Serum Level of Cytokine IL-30 in Psoriatic Patients and Correlation With Disease Severity
Main Article Content
Keywords
Psoriasis, Interleukin-30, Cytokines, Psoriasis pathogenesis, PASI
Abstract
Psoriasis is a common chronic immune-mediated inflammatory skin disorder characterized by
erythematous silvery scaling of the skin and associated severe itching. Reports indicate that
psoriasis is affecting about 2% of world population and life quality in a way that limits the
patient activity and thereby productivity in a community. Therefore, determining appropriate
therapeutics for psoriasis would make a difference in the lives of the patients and their
communities. To address this, scientists have been working on different biological agents, such
as interleukins and their antagonists, to regulate the common inflammatory process in psoriasis.
For the current research project, serum was collected from 26 psoriatic patients and another 26
health controls, and the serums were examined for the level of IL-30 to determine differences
among the tested groups and to investigate a possible correlation between IL-30 and PASI
(psoriasis area severity index). The study delineated differences of the IL-30 among the groups
and a positive correlation between IL-30 and PASI among the psoriatic cases, which insights a
need for further studies that include a large scale of participants to fully elucidate the
involvement of IL-30 in psoriasis.
References
1. Boehncke, W.H. and M.P. Schon, Psoriasis. Lancet, 2015. 386(9997): p. 983-94.
2. Xu, X. and H.Y. Zhang, The Immunogenetics of Psoriasis and Implications for Drug Repositioning. Int J Mol Sci, 2017. 18(12).
3. Hwang, S.T., T. Nijsten, and J.T. Elder, Recent Highlights in Psoriasis Research. J Invest Dermatol, 2017. 137(3): p. 550-556.
4. Takahashi, H., et al., Serum cytokines and growth factor levels in Japanese patients withpsori asis. Clin Exp Dermatol, 2010. 35(6): p.645-9.
5. Golinska, J., M. Sar-Pomian, and L. Rudnicka, Dermoscopic features of psoriasis of the skin, scalp and nails - a systematic review. J Eur Acad Dermatol Venereol, 2019. 33(4):p. 648-660.
6. Yeung, H., et al., Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol, 2013. 149(10): p. 1173-9.
7. Ayala-Fontanez, N., D.C. Soler, and T.S. McCormick, Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl), 2016. 6: p. 7-32.
8. Feldman, S.R., et al., The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. Am Health Drug Benefits, 2016. 9(9): p. 504-513.
9. Coondoo, A., Cytokines in dermatology - a basic overview. Indian J Dermatol, 2011.56(4): p. 368-74.
10. Kouris, A., et al., Proinflammatory cytokine responses in patients with psoriasis. Eur Cytokine Netw, 2014. 25(4): p. 63-8.
11. Krause, M.L., et al., Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis. Clin Immunol, 2011. 141(1): p. 67-72.
12. Catalan-Dibene, J., L.L. McIntyre, and A. Zlotnik, Interleukin 30 to Interleukin 40. J Interferon Cytokine Res, 2018. 38(10): p. 423-439.
13. Di Carlo, E., Decoding the Role of Interleukin-30 in the Crosstalk Between Cancer and Myeloid Cells. Cells, 2020. 9(3).
14. Petes, C., et al., Interleukin (IL)-6 Inhibits IL-27- and IL-30-Mediated Inflammatory Responses in Human Monocytes. Front Immunol, 2018. 9: p. 256.
15. Stumhofer, J.S., et al., A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol, 2010. 11(12): p. 1119-26.
16. Baran, P., et al., Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. J Biol Chem, 2013. 288(21): p. 14756-68.
17. Zhang, J., et al., Soluble expression and purification of the functional interleukin-30 protein in Escherichia coli. Prep Biochem Biotechnol, 2016. 46(6): p. 539-45.
18. Abdel-Hamid, M.F., et al., Serum levels of interleukin-8, tumor necrosis factor-alpha and gamma-interferon in Egyptian psoriatic patients and correlation with disease severity. J Dermatol, 2011. 38(5): p. 442-6.
19. Salman, A., et al., Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study. An Bras Dermatol, 2018. 93(6): p. 819-823.
20. Arican, O., et al., Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm, 2005. 2005(5): p. 273-9.
21. Asadullah, K., W. Sterry, and H.D. Volk, Analysis of cytokine expression in dermatology.Arch Dermatol, 2002. 138(9): p. 1189-96.
22. Kyriakou, A., et al., Serum levels of TNF-alpha, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J Immunol Res, 2014. 2014: p.467541.
23. Garbers, C., et al., Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev, 2012. 23(3): p. 85-97.
24. Liu, X., et al., A protective role of IL-30 via STAT and ERK signaling pathways in macrophage-mediated inflammation. Biochem Biophys Res Commun, 2013. 435(2): p.306-12.
25. Carlin, C.S., et al., A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol, 2004. 50(6): p. 859-66.
26. Spuls, P.I., et al., How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol, 2010. 130(4): p. 933-43.
27. Puzenat, E., et al., What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol, 2010. 24 Suppl 2: p. 10-6.
28. Kyriakou, A., et al., Serum levels of TNF- alpha , IL-12/23 p40, and IL-17 in psoriatic patients with and without nail psoriasis: a cross-sectional study. ScientificWorldJournal,2014. 2014: p. 508178.
29. Gudjonsson, J.E. and J.T. Elder, Psoriasis: epidemiology. Clin Dermatol, 2007. 25(6): p.535-46.
30. Fernandez-Armenteros, J.M., et al., Epidemiology of Psoriasis. A Population-Based Study. Actas Dermosifiliogr, 2019. 110(5): p. 385-392.
31. Kyriakou, A., A. Patsatsi, and D. Sotiriadis, Detailed analysis of specific nail psoriasis features and their correlations with clinical parameters: a cross-sectional study.Dermatology, 2011. 223(3): p. 222-9.
32. Gottlieb, A.B., C. Ryan, and J.E. Murase, Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol, 2019. 5(3): p. 141-150.
33. Hagg, D., et al., Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol, 2017. 18(4): p. 583-590.
34. Lopez-Estebaranz, J.L., J.L. Sanchez-Carazo, and S. Sulleiro, Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study. J Dermatol, 2016. 43(4): p. 395-401.
35. Baliwag, J., D.H. Barnes, and A. Johnston, Cytokines in psoriasis. Cytokine, 2015. 73(2):p. 342-50.
36. Kim, J. and J.G. Krueger, The immunopathogenesis of psoriasis. Dermatol Clin, 2015.33(1): p. 13-23.
37. Schon, M.P. and W.H. Boehncke, Psoriasis. N Engl J Med, 2005. 352(18): p. 1899-912.
2. Xu, X. and H.Y. Zhang, The Immunogenetics of Psoriasis and Implications for Drug Repositioning. Int J Mol Sci, 2017. 18(12).
3. Hwang, S.T., T. Nijsten, and J.T. Elder, Recent Highlights in Psoriasis Research. J Invest Dermatol, 2017. 137(3): p. 550-556.
4. Takahashi, H., et al., Serum cytokines and growth factor levels in Japanese patients withpsori asis. Clin Exp Dermatol, 2010. 35(6): p.645-9.
5. Golinska, J., M. Sar-Pomian, and L. Rudnicka, Dermoscopic features of psoriasis of the skin, scalp and nails - a systematic review. J Eur Acad Dermatol Venereol, 2019. 33(4):p. 648-660.
6. Yeung, H., et al., Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol, 2013. 149(10): p. 1173-9.
7. Ayala-Fontanez, N., D.C. Soler, and T.S. McCormick, Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl), 2016. 6: p. 7-32.
8. Feldman, S.R., et al., The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. Am Health Drug Benefits, 2016. 9(9): p. 504-513.
9. Coondoo, A., Cytokines in dermatology - a basic overview. Indian J Dermatol, 2011.56(4): p. 368-74.
10. Kouris, A., et al., Proinflammatory cytokine responses in patients with psoriasis. Eur Cytokine Netw, 2014. 25(4): p. 63-8.
11. Krause, M.L., et al., Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis. Clin Immunol, 2011. 141(1): p. 67-72.
12. Catalan-Dibene, J., L.L. McIntyre, and A. Zlotnik, Interleukin 30 to Interleukin 40. J Interferon Cytokine Res, 2018. 38(10): p. 423-439.
13. Di Carlo, E., Decoding the Role of Interleukin-30 in the Crosstalk Between Cancer and Myeloid Cells. Cells, 2020. 9(3).
14. Petes, C., et al., Interleukin (IL)-6 Inhibits IL-27- and IL-30-Mediated Inflammatory Responses in Human Monocytes. Front Immunol, 2018. 9: p. 256.
15. Stumhofer, J.S., et al., A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol, 2010. 11(12): p. 1119-26.
16. Baran, P., et al., Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. J Biol Chem, 2013. 288(21): p. 14756-68.
17. Zhang, J., et al., Soluble expression and purification of the functional interleukin-30 protein in Escherichia coli. Prep Biochem Biotechnol, 2016. 46(6): p. 539-45.
18. Abdel-Hamid, M.F., et al., Serum levels of interleukin-8, tumor necrosis factor-alpha and gamma-interferon in Egyptian psoriatic patients and correlation with disease severity. J Dermatol, 2011. 38(5): p. 442-6.
19. Salman, A., et al., Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study. An Bras Dermatol, 2018. 93(6): p. 819-823.
20. Arican, O., et al., Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm, 2005. 2005(5): p. 273-9.
21. Asadullah, K., W. Sterry, and H.D. Volk, Analysis of cytokine expression in dermatology.Arch Dermatol, 2002. 138(9): p. 1189-96.
22. Kyriakou, A., et al., Serum levels of TNF-alpha, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J Immunol Res, 2014. 2014: p.467541.
23. Garbers, C., et al., Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev, 2012. 23(3): p. 85-97.
24. Liu, X., et al., A protective role of IL-30 via STAT and ERK signaling pathways in macrophage-mediated inflammation. Biochem Biophys Res Commun, 2013. 435(2): p.306-12.
25. Carlin, C.S., et al., A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol, 2004. 50(6): p. 859-66.
26. Spuls, P.I., et al., How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol, 2010. 130(4): p. 933-43.
27. Puzenat, E., et al., What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol, 2010. 24 Suppl 2: p. 10-6.
28. Kyriakou, A., et al., Serum levels of TNF- alpha , IL-12/23 p40, and IL-17 in psoriatic patients with and without nail psoriasis: a cross-sectional study. ScientificWorldJournal,2014. 2014: p. 508178.
29. Gudjonsson, J.E. and J.T. Elder, Psoriasis: epidemiology. Clin Dermatol, 2007. 25(6): p.535-46.
30. Fernandez-Armenteros, J.M., et al., Epidemiology of Psoriasis. A Population-Based Study. Actas Dermosifiliogr, 2019. 110(5): p. 385-392.
31. Kyriakou, A., A. Patsatsi, and D. Sotiriadis, Detailed analysis of specific nail psoriasis features and their correlations with clinical parameters: a cross-sectional study.Dermatology, 2011. 223(3): p. 222-9.
32. Gottlieb, A.B., C. Ryan, and J.E. Murase, Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol, 2019. 5(3): p. 141-150.
33. Hagg, D., et al., Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol, 2017. 18(4): p. 583-590.
34. Lopez-Estebaranz, J.L., J.L. Sanchez-Carazo, and S. Sulleiro, Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study. J Dermatol, 2016. 43(4): p. 395-401.
35. Baliwag, J., D.H. Barnes, and A. Johnston, Cytokines in psoriasis. Cytokine, 2015. 73(2):p. 342-50.
36. Kim, J. and J.G. Krueger, The immunopathogenesis of psoriasis. Dermatol Clin, 2015.33(1): p. 13-23.
37. Schon, M.P. and W.H. Boehncke, Psoriasis. N Engl J Med, 2005. 352(18): p. 1899-912.
Article Sidebar
Published
Oct 17, 2021
Article Details
How to Cite
Nergez Sabah Omar, Long Xinxin, Xian Jiayi, Saeed Ghulam Hussain, & Peng xue biao. (2021). Serum Level of Cytokine IL-30 in Psoriatic Patients and Correlation With Disease Severity. Journal of Population Therapeutics and Clinical Pharmacology, 28(01). https://mail.jptcp.com/index.php/jptcp/article/view/823
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Nergez Sabah Omar, Long Xinxin, Xian Jiayi, Saeed Ghulam Hussain, & Peng xue biao. (2021). Serum Level of Cytokine IL-30 in Psoriatic Patients and Correlation With Disease Severity. Journal of Population Therapeutics and Clinical Pharmacology, 28(01). https://mail.jptcp.com/index.php/jptcp/article/view/823